You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lung Adenocarcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Local and Peripheral Immune Responsive Landscape Induced by

Not yet recruiting
  • Lung Adenocarcinoma
  • Local Cryoablation
    • (no location specified)
    Oct 24, 2023

    Tumor Microenvironment

    Active, not recruiting
    • Lung Adenocarcinoma
      • (no location specified)
      Aug 5, 2023

      Lung Adenocarcinoma Trial in Shijiazhuang (Tislelizumab,Platinum)

      Recruiting
      • Lung Adenocarcinoma
      • Shijiazhuang, Hebei, China
        The Fourth Hospital of Hebei Medical University (Hebei Tumor Hos
      Sep 24, 2023

      IA Lung Adenocarcinoma, Combined Segmentectomy Trial in Fuzhou (Patients receive subsegmentectomy)

      Active, not recruiting
      • IA Lung Adenocarcinoma
      • Combined Segmentectomy
      • Patients receive subsegmentectomy
      • Fuzhou, China
        Fujian Medical University Union Hospital
      Aug 2, 2023

      Invasiveness for Small-sized Lung Adenocarcinoma

      Recruiting
      • Lung Adenocarcinoma, Stage I
      • Invasiveness diagnosis
      • Wuhan, Hubei, China
        Union Hospital, Tongji Medical College, Huazhong University of S
      Apr 13, 2023

      Segmentectomy Versus Lobectomy for Lung Adenocarcinoma = 2cm

      Recruiting
      • Lung Adenocarcinoma
      • Lobectomy with systemic lymph node dissection
      • Segmentectomy with systemic lymph node dissection
      • Yangpu, Shanghai, China
        Shanghai Pulmonary Hospital
      Apr 20, 2023

      Intraoperative Frozen Section Pathology to Guide Surgical

      Recruiting
      • Lung Adenocarcinoma
      • +2 more
      • Surgical resection
      • Shanghai, Shanghai, China
        Fudan University Cancer Center
      Mar 20, 2023

      Intraoperative Frozen Section Pathology to Guide Surgical

      Recruiting
      • Lung Adenocarcinoma
      • +2 more
      • Surgical resection
      • Shanghai, Shanghai, China
        Fudan University Cancer Center
      Mar 31, 2023

      Novel Grading System of Resected Lung Adenocarcinoma

      Recruiting
      • Lung Adenocarcinoma
      • +2 more
      • Whole Slide Image based Deep Learning Signature
      • Zunyi, Guizhou, China
      • +2 more
      Jun 27, 2023

      Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)

      Not yet recruiting
      • Lung Adenocarcinoma
      • +3 more
      • Serplulimab and Bevacizumab injection
      • (no location specified)
      Dec 21, 2022

      Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)

      Not yet recruiting
      • Non-small Cell Lung Adenocarcinoma
      • Squamous Cell Carcinoma of Lung
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Center
      Jul 5, 2023

      ALK-positive NSCLC Trial in Dallas (Ceritinib, Stereotactic ablative body radiation)

      Terminated
      Has Results
      • ALK-positive Non-small Cell Lung Cancer
      • Dallas, Texas
        UT Southwestern Medical Center
      Jan 31, 2023

      Intraoperative Frozen Section Pathology to Guide Surgical

      Recruiting
      • Lung Adenocarcinoma
      • +2 more
      • Surgical resection
      • Shanghai, Shanghai, China
        Fudan University Cancer Center
      Mar 20, 2023

      Novel Grading System of Clinical Stage I Lung Adenocarcinoma

      Recruiting
      • Lung Adenocarcinoma
      • +2 more
      • PET/CT-based Radiomics Signature
      • Zunyi, Guizhou, China
      • +3 more
      Feb 12, 2023

      NSCLC Metastatic Trial (Atezolizumab, Nab paclitaxel, Carboplatin)

      Not yet recruiting
      • Non-Small Cell Lung Cancer Metastatic
      • (no location specified)
      Jan 18, 2023

      Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)

      Recruiting
      • Lung Adenocarcinoma Stage III
      • +2 more
      • Shanghai, Shanghai, China
        Shanghai Pulmonary Hospital
      Aug 13, 2022

      Lung Adenocarcinoma, Frozen Section, Sublobar Resection Trial in Shanghai (Sublobar Resection)

      Recruiting
      • Lung Adenocarcinoma
      • +2 more
      • Sublobar Resection
      • Shanghai, Shanghai, China
        Fudan University Cancer Center
      Sep 4, 2023

      Radiomics Combined With Frozen Section Prediction Model for

      Not yet recruiting
      • Lung Adenocarcinoma
      • radiomics
      • (no location specified)
      Jun 22, 2022

      NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • Phase I - Mirdametinib - Level 1
      • +4 more
      • (no location specified)
      Jul 7, 2023

      Real-world Data of Afatinib Treatment in First-line Setting and

      Active, not recruiting
      • Non-squamous, Non-Small Cell Lung Cancer
      • Tokyo, Japan
        Nippon Boehringer Ingelheim Co., Ltd.
      Jan 9, 2023

      IASLC Grading System as a Predictor for EGFR-TKI Therapy

      Completed
      • Lung Cancer
      • IASLC grading system
      • Shanghai, Please Select, China
        Chaoqiang Deng
      Nov 9, 2023

      Adenocarcinoma of Lung Trial in United States (NovoTTF-200T System)

      Not yet recruiting
      • Adenocarcinoma of Lung
      • NovoTTF-200T System
      • Basking Ridge, New Jersey
      • +6 more
      Mar 3, 2023

      Segmentectomy, Lung Adenocarcinoma Trial (Segmentectomy)

      Not yet recruiting
      • Segmentectomy
      • Lung Adenocarcinoma
      • Segmentectomy
      • (no location specified)
      Jan 29, 2023

      Lung Adenocarcinoma Stage III Trial in Shanghai (HS-10296 (Almonertinib))

      Recruiting
      • Lung Adenocarcinoma Stage III
      • HS-10296 (Almonertinib)
      • Shanghai, Shanghai, China
        Shanghai Pulmonary Hospital
      Mar 17, 2022

      ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy Trial in Changsha (Pembrolizumab Combined With Bevacizumab and

      Not yet recruiting
      • ALK Gene Mutation
      • +2 more
      • Pembrolizumab Combined With Bevacizumab and Chemotherapy
      • Changsha, Hunan, China
        Hunan Cancer Hospital
      Jul 14, 2022